Salbutamol HFA-152a

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

AsthmaHealthy ParticipantsMild Asthma

Phase 1

Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants

CompletedNCT05791565

GlaxoSmithKlineAsthma

Start: 2023-04-03End: 2023-05-21Updated: 2024-09-23

A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive

CompletedNCT06433908

GlaxoSmithKlineAsthma, Healthy Participants

Start: 2024-06-04End: 2024-10-22Updated: 2026-01-12

A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive

RecruitingNCT06433921

GlaxoSmithKlineAsthma, Mild Asthma

Start: 2024-08-14End: 2027-02-26Target: 84Updated: 2026-06-24

Phase 3

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

CompletedNCT06261957

GlaxoSmithKlineAsthma

Start: 2024-05-31End: 2025-09-02Updated: 2026-02-27

Related Papers

Developing low-carbon salbutamol MDI: assessment of relative bioavailability and pharmacodynamic relative potency of salbutamol MDI with propellant HFA-152a.

2026-06-17